First RSV Vaccine On The Horizon—Pfizer Touts Strong Trial Results As Children’s Hospitals Count Soaring Cases Pfizer said the vaccine, which is given to pregnant people to protect infants from birth, was safe, well-tolerated and had an efficacy of nearly 70% against severe respiratory illness from RSV in the first six months of life.